{"id":"W2736712994","doi":"10.1016/s0923-7534(20)33023-4","title":"A Phase I Study of Daily Afatinib, an Irreversible Erbb Family Blocker, Combined With Weekly Paclitaxel and 2-Weekly Bevacizumab in Patients with Advanced Solid Tumours","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Bevacizumab; Afatinib; Paclitaxel; ErbB; Oncology; Internal medicine; Pharmacology; Chemotherapy; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001346143,0.001597486,0.003371328,0.0006489219,0.0005700475,0.001298991,0.001127899,0.001722831,0.003934645],"category_scores_gemma":[0.001281779,0.0009953893,0.00231532,0.0005641817,0.001223471,0.001521774,0.0003652693,0.005204221,0.001196393],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001171498,"about_ca_system_score_gemma":0.001509378,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001527756,"about_ca_topic_score_gemma":0.00360411,"domain_scores_codex":[0.9995031,0.0001905696,0.00002508267,0.0001211892,0.00003623683,0.0001237609],"domain_scores_gemma":[0.9989631,0.0001840604,0.0001351438,0.00009541665,0.00005799402,0.0005642388],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8037701,0.07651729,0.002807263,0.000802036,0.002395167,0.0002023165,0.0003168217,0.003015355,0.02795973,0.0003571117,0.00411637,0.07774052],"study_design_scores_gemma":[0.7304434,0.2609518,0.00416006,0.0000191959,0.0004632752,0.0001683133,0.0000502662,0.0008446762,0.00129867,0.0001978753,0.001367985,0.00003452035],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916781,0.002124345,0.0006006322,0.0008500998,0.0003113879,0.001580253,0.0007656665,0.0001310649,0.001958356],"genre_scores_gemma":[0.9887007,0.002058607,0.001879543,0.001005435,0.000254586,0.001623871,0.001424586,0.00005748414,0.002995168],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003934645,"threshold_uncertainty_score":0.01316273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03840019905791524,"score_gpt":0.4007713939528871,"score_spread":0.3623711948949719,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}